PTK/ZK Not Dead Yet; R&D Efforts May Shift To Subgroup, Novartis Says
Executive Summary
Novartis/Schering AG may shift development of their investigational colorectal cancer agent PTK/ZK 787 (valatanib) to focus on patients with elevated lactate dehydrogenase (LDH) levels, Novartis Oncology President David Epstein said June 7